Document:

Document

Exhibit 10.1

CONSULTING AGREEMENT
THIS CONSULTING AGREEMENT (the “Agreement”) is made as of February 1, 2021 (the “Effective Date”) by and between Viridian Therapeutics, Inc., a Delaware corporation with a principal business address at 6200 Lookout Road, Boulder, CO 80301, (the “Company”), and William S. Marshall, Ph.D. with an address at [intentionally omitted] (“Consultant”). Company desires to have the benefit of Consultant’s knowledge and experience, and Consultant desires to provide services to Company, all as provided in this Agreement.
1.Services. Company retains Consultant, and Consultant agrees to provide, consulting and advisory services to the Company as the Company may from time to time reasonably request and as specified in the Business Terms Exhibit, attached hereto as Exhibit A. (the “Consulting Services”). Any changes to the Consulting Services (and any related compensation adjustments) must be agreed to in writing between Consultant and the Company prior to implementation of the changes. 
2.Compensation. As full consideration for Consulting Services provided under this Agreement, Company agrees to pay Consultant and reimburse expenses as described in Exhibit A. 
3.Performance. Consultant agrees to provide the Consulting Services to the Company, or to its designee, in accordance with all applicable laws and regulations and the highest professional standards. Consultant represents and warrants that Consultant has not been, and is not under consideration to be (a) debarred from providing services pursuant to Section 306 of the United States Federal Food Drug and Cosmetic Act, 21 U.S.C. § 335a; (b) excluded, debarred or suspended from, or otherwise ineligible to participate in, any federal or state health care program or federal procurement or non-procurement programs (as that term is defined in 42 U.S.C. § 1320a-7b(f)); (c) disqualified by any government or regulatory agencies from performing specific services, and is not subject to a pending disqualification proceeding; or (d) convicted of a criminal offense related to the provision of health care items or services, or under investigation or subject to any such action that is pending.
4.Compliance with Obligations to Third Parties. Consultant represents and warrants to the Company that the terms of this Agreement and Consultant’s performance of Consulting Services do not and will not conflict with any of Consultant’s obligations to any third parties. Consultant agrees not to use any trade secrets or other confidential information of any other person, firm, corporation, institution or other third party in connection with any of the Consulting Services. If Consultant is an employee of another company or institution, Consultant represents and warrants that Consultant is permitted to enter into this Agreement pursuant to such company’s or institution’s policies concerning professional consulting and additional workload. Consultant agrees not to make any use of any funds, space, personnel, facilities, equipment or other resources of a third party in performing the Consulting Services, nor take any other action that would result in a third party asserting ownership of, or other rights in, any Work Product (defined in Section 5), unless agreed upon in writing in advance by the Company.
5.Work Product. Consultant will promptly and fully disclose in confidence to the Company all inventions, discoveries, improvements, ideas, concepts, designs, processes, formulations, products, computer programs, works of authorship, databases, mask works, trade secrets, know-how, information, data, documentation, reports, research, creations and other products arising from or made in the performance of (solely or jointly with others) the Consulting Services (whether or not patentable or subject to copyright or trade secret protection) (collectively, the “Work Product”). 
CONFIDENTIAL
Page 1 of 7

Consultant assigns and agrees to assign to the Company all rights in the United States and throughout the world to Work Product. Consultant will keep and maintain adequate and current written records of all Work Product, and such records will be available to and remain the sole property of the Company at all times. For purposes of the copyright laws of the United States, Work Product will constitute “works made for hire,” except to the extent such Work Product cannot by law be “works made for hire”. Consultant represents and warrants that Consultant has and will have the right to transfer and assign to Company ownership of all Work Product. Consultant will execute all documents, and take any and all actions needed, all without further consideration, in order to confirm the Company’s rights as outlined above. In the event that the Consultant should fail or refuse to execute such documents within a reasonable time, Consultant appoints the Company as attorney to execute and deliver any such documents on Consultant’s behalf.
6.Confidentiality. 
(a)“Confidential Information” means (i) any non-public scientific, technical, business or financial information or trade secrets in whatever form (written, oral or visual) that is furnished or made available to Consultant by or on behalf of the Company, (ii) all information contained in or comprised of Company Materials (defined in Section 7); and (iii) all Work Product. Confidential Information is, and will remain, the sole property of the Company. 
(b)During the Term (as defined in Section 9) and for a period of five (5) years thereafter, Consultant agrees to (i) hold in confidence all Confidential Information, and not disclose Confidential Information without the prior written consent of the Company; (ii) use Confidential Information solely in connection with the Consulting Services; (iii) treat Confidential Information with no less than a reasonable degree of care; (iv) reproduce Confidential Information solely to the extent necessary to provide the Consulting Services, with all such reproductions being considered Confidential Information; and (v) notify the Company of any unauthorized disclosure of Confidential Information promptly upon becoming aware of such disclosure. Notwithstanding the foregoing, the non-disclosure and non-use obligations imposed by this Agreement with respect to trade secrets included in the Confidential Information will continue for as long as the Company continues to treat such Confidential Information as a trade secret.
(c)Consultant’s obligations of non-disclosure and non-use under this Agreement will not apply to any portion of Confidential Information that Consultant can demonstrate, by competent proof:
(i)is generally known to the public at the time of disclosure or becomes generally known through no wrongful act on the part of Consultant;
(ii)is in Consultant’s possession at the time of disclosure other than as a result of Consultant’s breach of any legal obligation;
(iii)becomes known to Consultant on a non-confidential basis through disclosure by sources other than the Company having the legal right to disclose such Confidential Information; or
(iv)is independently developed by Consultant without reference to or reliance upon Confidential Information.
CONFIDENTIAL
Page 2 of 7

(d)If Consultant is required by a governmental authority or by order of a court of competent jurisdiction to disclose any Confidential Information, Consultant will give Company prompt written notice thereof and Consultant will take all reasonable and lawful actions to avoid or minimize the degree of such disclosure. Consultant will cooperate reasonably with the Company in any efforts to seek a protective order.
(e)Company provides notice to Consultant that pursuant to the United States Defend Trade Secrets Act of 2016:
(i)An individual will not be held criminally or civilly liable under any United States federal or state trade secret law for the disclosure of a trade secret that is made (A) in confidence to a federal, state, or local government official or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law; or (B) in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal; and
(ii)An individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the individual (A) files any document containing the trade secret under seal; and (B) does not disclose the trade secret, except pursuant to court order.
(f)In addition, this Agreement does not prohibit Consultant from participating in or cooperating with any government investigation or proceeding, nor does this Agreement restrict Consultant from disclosing Confidential Information to government agencies in a reasonable manner when permitted by applicable state or federal “whistleblower” or other laws. 
7.Company Materials. All documents, data, records, materials, compounds, apparatus, equipment and other physical property furnished or made available by or on behalf of the Company to Consultant in connection with this Agreement (“Company Materials”) are and will remain the sole property of the Company. Consultant will use the Company Materials only as necessary to perform the Consulting Services and will not transfer or make available to any third party the Company Materials without the express prior written consent of Company. Consultant will return to Company any and all Company Materials upon request.
8.Publication; Publicity. Consultant may not publish or refer to Work Product, in whole or in part, without the prior express written consent of Company. Consultant will not use the name, logo, trade name, service mark, or trademark, or any simulation, abbreviation, or adaptation of same, or the name of Company or any of its affiliates for publicity, promotion, or other uses without Company’s prior written consent.
9.Expiration/Termination. The term of this Agreement will commence on the Effective Date and expire at the end of the period specified in the Exhibit A, unless sooner terminated pursuant to the provisions of this Section 9 or extended by mutual written agreement of the parties (the “Term”). Viridian may terminate this Agreement at any time with or without cause upon not less than ten (10) days’ prior written notice to Consultant. Consultant may terminate this Agreement at any time with or without cause upon not less than sixty (60) days’ prior written notice to Viridian. Any expiration or termination of this Agreement shall be without prejudice to any obligation of either 
CONFIDENTIAL
Page 3 of 7

party that has accrued prior to the effective date of expiration or termination. Upon expiration or termination of this Agreement, neither Consultant nor Company will have any further obligations under this Agreement, except that (a) Consultant will terminate all Consulting Services in progress in an orderly manner as soon as practicable and in accordance with a schedule agreed to by the Company, unless the Company specifies in the notice of termination that Consulting Services in progress should be completed; (b) Consultant will deliver to the Company all Work Product made through expiration or termination; (c) the Company will pay Consultant any monies due and owing Consultant, up to the time of termination or expiration, for Consulting Services properly performed and all authorized expenses actually incurred; (d) Consultant will immediately return to Company all Company Materials and other Confidential Information and copies thereof provided to Consultant under this Agreement; and (e) the terms, conditions and obligations under Sections 3, 5, 6, 7, 8, 9 and 10 will survive expiration or termination of this Agreement.
10.Miscellaneous.
(a)Independent Contractor. The parties understand and agree that Consultant is an independent contractor and not an agent or employee of the Company. Consultant has no authority to obligate Company by contract or otherwise. Consultant will not be eligible for any employee benefits of Company and expressly waives any rights to any employee benefits. Consultant will bear sole responsibility for paying and reporting Consultant’s own applicable federal and state income taxes, social security taxes, unemployment insurance, workers’ compensation, and health or disability insurance, retirement benefits, and other welfare or pension benefits, if any, and indemnifies and holds the Company harmless from and against any liability with respect to such taxes, benefits and other matters.
(b)Use of Name. Consultant consents to the use by the Company of Consultant’s name on its website, in press releases, company brochures, offering documents, presentations, reports or other documents in printed or electronic form, and any documents filed with or submitted to any governmental or regulatory agency or any securities exchange or listing entity; provided, that such materials or presentations accurately describe the nature of Consultant’s relationship with or contribution to the Company.
(c)Entire Agreement. This Agreement contains the entire agreement of the parties with regard to its subject matter and supersedes all prior or contemporaneous written or oral representations, agreements and understandings between the parties relating to that subject matter. This Agreement may be changed only by a writing signed by Consultant and an authorized representative of Company.
(d)Certain Disclosures and Transparency. Consultant acknowledges that the Company and its affiliates are required to abide by federal and state disclosure laws and certain transparency policies governing their activities including providing reports to the government and to the public concerning financial or other relationships with healthcare providers. Consultant agrees that the Company and its affiliates may, in their sole discretion, disclose information about this Agreement and about Consultant’s Consulting Services including those relating to healthcare providers and any compensation paid to healthcare providers pursuant to this Agreement. Consultant agrees to promptly supply information reasonably requested by Company for disclosure purposes. To the extent that Consultant is independently obligated to disclose specific information concerning the Consulting Services relating to healthcare 
CONFIDENTIAL
Page 4 of 7

providers and compensation paid to healthcare providers pursuant to this Agreement, Consultant will make timely and accurate required disclosures. 
(e)Assignment and Binding Effect. The Consulting Services to be provided by Consultant are personal in nature. Consultant may not assign or transfer this Agreement or any of Consultant’s rights or obligations hereunder. In no event will Consultant assign or delegate responsibility for actual performance of the Consulting Services to any third party. The Company may transfer or assign this Agreement, in whole or in part, without the prior written consent of Consultant. Any purported assignment or transfer in violation of this Section is void. This Agreement will be binding upon and inure to the benefit of the parties and their respective legal representatives, heirs, successors and permitted assigns.
(f)Notices. All notices required or permitted under this Agreement must be in writing and must be given by directing the notice to the address for the receiving party set forth in this Agreement or at such other address as the receiving party may specify in writing under this procedure. Notices to Company will be marked “Attention: Legal Department”. All notices must be given (i) by personal delivery, with receipt acknowledged, (ii) by prepaid certified or registered mail, return receipt requested, or (iii) by prepaid recognized next business day delivery service. Notices will be effective upon receipt or at a later date stated in the notice.
(g)Governing Law. This Agreement and any disputes relating to or arising out of this Agreement will be governed by, construed, and interpreted in accordance with the internal laws of the State of Delaware, without regard to any choice of law principle that would require the application of the law of another jurisdiction. The parties agree to submit to the exclusive jurisdiction of the state and federal courts located in the State of Delaware and waive any defense of inconvenient forum to the maintenance of any action or proceeding in such courts.
(h)Severability; Reformation. Each provision in this Agreement is independent and severable from the others, and no provision will be rendered unenforceable because any other provision is found by a proper authority to be invalid or unenforceable in whole or in part. If any provision of this Agreement is found by such an authority to be invalid or unenforceable in whole or in part, such provision shall be changed and interpreted so as to best accomplish the objectives of such unenforceable or invalid provision and the intent of the parties, within the limits of applicable law.
(i)No Strict Construction; Headings. This Agreement has been prepared jointly and will not be strictly construed against either party. The section headings are included solely for convenience of reference and will not control or affect the meaning or interpretation of any of the provisions of this Agreement.
(j)Waivers. Any delay in enforcing a party’s rights under this Agreement, or any waiver as to a particular default or other matter, will not constitute a waiver of such party’s rights to the future enforcement of its rights under this Agreement, except with respect to an express written waiver relating to a particular matter for a particular period of time signed by Consultant and an authorized representative of the waiving party, as applicable.
(k)Remedies. Consultant agrees that (i) the Company may be irreparably injured by a breach of this Agreement by Consultant; (ii) money damages would not be an adequate remedy for 
CONFIDENTIAL
Page 5 of 7

any such breach; (iii) as a remedy for any such breach the Company will be entitled to seek equitable relief, including injunctive relief and specific performance, without being required by Consultant to post a bond; and (iv) such remedy will not be the exclusive remedy for any breach of this Agreement.
(l)Counterparts. This Agreement may be executed in any number of counterparts, each of which will be deemed an original, including via e-mail delivery of a portable document data file (“.pdf”) or similar electronic means, but all of which together constitute one and the same instrument. 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the Effective Date.

												
	VIRIDIAN THERAPEUTICS, INC.
		William S. Marshall, Ph.D.

				
	By:	/s/ Jason Leverone		/s/ William S. Marshall
				
	Name: Jason Leverone		
				
	Title: Chief Financial Officer		

CONFIDENTIAL
Page 6 of 7

EXHIBIT A
BUSINESS TERMS 
1.Consulting Services: 
The Consultant shall provide Consulting Services to the Company generally as a member of the CVR Special Committee in accordance with the Contingent Value Rights Agreement dated October 27, 2020.  
Consultant will provide Consulting Services on a schedule and at a location or locations indicated above or as otherwise mutually agreed between Consultant and Company. In addition, Consultant will be available for a reasonable number of telephone and/or written consultations.
2.Compensation:
Fees:  Viridian will pay Consultant $400/hour, not to exceed thirty (30) hours per month without Viridian express written consent.  
Expenses: Company will reimburse Consultant for any pre-approved expenses actually incurred by Consultant in connection with the provision of Consulting Services. Requests for reimbursement will be in a form reasonably acceptable to the Company, will include supporting documentation and will accompany Consultant’s invoices.
Invoicing: No later than the last day of each calendar month, Consultant will invoice Company for Consulting Services rendered and related expenses incurred during the preceding month. Invoices should reference this Agreement and should be submitted to Company to the attention of: ap@viridiantherapeutics.com. Invoices will contain such detail as Company may reasonably require and will be payable in U.S. Dollars. Undisputed payments will be made by Company within thirty (30) days after Company’ receipt of Consultant’s invoice, request for reimbursement and all supporting documentation.
3.Term:
This Agreement will be for a term of six (6) months beginning on the Effective Date.
CONFIDENTIAL
Page 7 of 7Document

Exhibit 10.4

FIFTH ADDENDUM

THIS ADDENDUM, made and entered into this 26th day of March, 2021, to that Lease dated December 16, 2010, by and between CRESTVIEW, LLC, a Colorado limited liability company (herein called “Landlord”) and VIRIDIAN THERAPEUTICS, INC., a Delaware corporation (f/k/a MIRAGEN THERAPEUTICS, INC.) (herein called “Tenant”).

The parties hereto agree to modify said Lease, effective as of the date of last signature below, as follows:

1.Paragraphs 1n and 1u are modified to read as follows:

n.    "Primary Lease Term." The term of the Lease shall commence at 12:01 a.m. on the 1st day of January, 2011 and shall terminate at 12:00 midnight on the 31st day of December, 2024, a term of fourteen (14) years.

u. “Tenant’s Notice Address” shall mean 6200 Lookout Road, Boulder, CO, 80301, Attention: Legal Department.”

2.    Paragraph 4 is modified to read as follows:

RENT.  Tenant agrees to pay to Landlord as Base Rent, without prior notice or demand, the following amounts:
Schedule of Base Rent

															
	Month(s)		Monthly Base Rent		Annual Base Rent
					
	January 2011-May 2011		$15,627.50		$78,137.50 (Only 5 Months)
					
	June 2011-May 2012		$15,627.50		$187,530.00
					
	June 2012-May 2013		$16,174.46		$194,093.52
					
	June 2013-May 2014		$16,740.57		$200,886.84
					
	June 2014-May 2015		$17,326.49		$207,917.88
					
	June 2015-September 2015		$16,185.63		$64,742.52 (Only 4 Months)
					
	October 2015		$18,262.20		$18,262.20 (Only 1 Month)
					
	November 2015		$26,914.54		$26,914.54 (Only 1 Month)
					
	December 2015-November 2016		$26,914.54		$322,974.48
					
	December 2016-November 2017		$31,481.79		$377,781.48
					
	December 2017-November 2018		$32,504.95		$390,059.40
					

															
	December 2018-November 2019		$33,561.36		$402,736.32
					
	December 2019-December 2020		$34,652.10		$450,477.30 (13 Months)
					
	January 2021-December 2021		$35,778.29		$429,339.48
					
	January 2022-December 2022		$39,561.67		$474,740.04
					
	January 2023-December 2023		$40,946.33		$491,355.96
					
	January 2024-December 2024		$42,379.45		$508,553.40
					
	Total Base Rent:				$4,826,502.86

Tenant shall begin to pay the Base Rent on the date the Primary Lease Term commences and thereafter on the first day of each month during the term hereof. Except as provided herein, all Rents shall be paid in advance, without notice, set off, abatement, counterclaim, deduction or diminution, at The Colorado Group, Inc., 3434 47th Street, Suite 220, Boulder, Colorado 80301, Attn: Susan Chrisman, or at such place as Landlord, from time-to-time, designates in writing. In addition, Tenant shall pay to Landlord Tenant's Pro Rata Share of Operating Expenses as provided herein and such other charges as are required by the terms of this Lease to be paid by Tenant which shall be referred to herein as "Additional Rent." Landlord shall have the same rights as to the Additional Rent as it has in the payment of Base Rent.  At no time shall Tenant’s Rent obligation be less than the Base Rent amount set forth above.

3.    Paragraph 32a is modified to read as follows:

a.     Landlord agrees to provide an allowance of $50,000 to be applied towards Base Rent, or for future Alterations of the Premises, as approved by both Tenant and Landlord. Any reasonable request for approval by the Tenant for Alternations should not be unreasonably withheld by the Landlord.  The Alterations shall be subject to the provisions of Paragraph 9 above.  Landlord’s architect, JM Associates, shall prepare all necessary construction drawings, including engaging any mechanical, structural and electrical engineers, as necessary, for the construction of the Alterations.  The cost of the architect and engineers shall be deducted from the allowance.  All construction shall be done by Landlord’s approved general contractor, CCM Construction, or any future approved general contractors, provided, however, Landlord’s general contractor shall use Walrath, CSC, Long Technology, Design Mechanical or Innovative Air for any HVAC Alterations.  All pricing shall be conducted on an open book basis.  Tenant shall have the right to review all quotes for commercial reasonableness.  If Tenant believes any of the major portions of the bid is not commercially reasonable, Landlord shall require the general contractor to obtain up to two additional bids from subcontractors for that portion of the bid.  The cost of the construction shall be deducted from the allowance and Tenant shall be responsible for any costs in excess of the allowance for Tenant approved Alternations.  If Tenant elects to use the allowance towards Base Rent, Tenant can apply not more than $25,000 per month.     

4.    Other than as modified herein, all terms and conditions of the Lease shall remain unchanged.  Capitalized terms used herein but not otherwise defined shall have the respective meanings given to them in the Lease.

IN WITNESS WHEREOF, the undersigned have executed this document as of the date above written.

															
	LANDLORD:
		TENANT:

	CRESTVIEW, LLC
		VIRIDIAN THERAPEUTICS, INC.
					
					
	By:	/s/ Steven Chrisman		By:	/s/ Jason Leverone
		Steven P. Chrisman			Jason A. Leverone
		Manager			Chief Financial Officer
		864 W. South Boulder Road, Suite 200			6200 Lookout Road
		Louisville, Colorado 80027			Boulder, Colorado 80301
		Tax I.D. 84-1445718			Tax I.D. 20-4362468

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}]]